Previously, one day before the second International Human Genome Editors' Summit, He Jiankui announced that a pair of genetically edited twin sisters named Lulu and Nana were born in China in November. This is the world's first genetically edited baby with immune AIDS.
However, once this news was reported, it caused an uproar, and people discussed the ethical issues very fiercely. Recently, a US company announced that it will launch a gene editing and treatment program, which has been accepted by US regulatory authorities and has no controversial ethical issues.
According to Xinhua News Agency, the American gene editing company Editas Pharmaceuticals announced that it will launch a clinical trial using CRISPR gene editing technology to treat a hereditary eye disease. The relevant applications have been accepted by US regulatory authorities.
According to reports, in the clinical trials approved by the company, the genetic editing object is the photoreceptor cells in the eyes of patients with congenital sputum, which is a somatic cell, not a germ cell. The genetic information of somatic cells is not passed on to the next generation, so ethical issues are not involved.
It is understood that Lieber congenital sable is a hereditary retinal degenerative disease caused by multiple genetic mutations, which is the most common cause of congenital blindness in children. Two to three out of every 100,000 children worldwide suffer from this disease. disease. At present, there is no effective treatment for this congenital disease.
Wenzhou Celecare Medical Instruments Co.,Ltd , https://www.wzcelecare.com